Evaluating Neutrophil-Lymphocyte Ratio in Bladder Cancer Treatment
Nordic Cystectomy Study I - Prospective Validation of Neutrophil/Lymphocyte Ratio as Predictor of Bladder Cancer Survival Risk After Radical Cystectomy for Bladder Cancer
This study is testing if the neutrophil-lymphocyte ratio can help doctors better understand how muscle invasive bladder cancer patients will respond to treatment before they have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 230 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Turku University Hospital Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Turku, Southwest Finland) |
| Trial ID | NCT04523025 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with muscle invasive bladder cancer who are planned to undergo radical cystectomy, with or without neoadjuvant chemotherapy. It aims to assess the neutrophil-lymphocyte ratio (NLR) as a potential prognostic marker to improve individual risk assessments and treatment planning. By analyzing the NLR in relation to treatment outcomes, the study seeks to enhance understanding of tumor response to chemotherapy and surgical interventions. The study will involve multiple centers across the Nordic countries to gather a comprehensive dataset.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with histologically confirmed urinary bladder cancer scheduled for radical cystectomy.
Not a fit: Patients undergoing radical cystectomy for reasons other than bladder cancer or those unwilling to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better prognostic assessments for patients with muscle invasive bladder cancer.
How similar studies have performed: While the specific approach of using NLR in this context may be novel, similar studies have shown promise in utilizing biomarkers for prognostic assessments in cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed urinary BC planned to be treated with RC with or without neoadjuvant chemotherapy. 2. Histologically confirmed urinary BC planned to be treated with palliative cystectomy 2) Signed informed consent 3) Patient age \>18 years Exclusion Criteria: 1. RC for other reasons than BC 2. Other forms of surgical treatment of BC than RC (e.g. bladder resection). 3. Patient unwillingness to participate in the study for any reason (i.e. lack of signed consent).
Where this trial is running
Turku, Southwest Finland
- University Hospital of Turku, Hospital Distric of Southwest Finland — Turku, Southwest Finland, Finland (Recruiting)
Study contacts
- Principal investigator: Peter Boström, MD, PhD — Turku University Hospital
- Study coordinator: Otto Ettala, MD, PhD
- Email: otto.ettala@tyks.fi
- Phone: 23130280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.